AXTI Plunges 8.2%; GF Value $2.57 Flags Extreme Overvaluation as Permits Remain Gating

What happened

AXT Inc. shares fell 8.2% to $84.31 on June 18, extending a 20.4% decline, as a GuruFocus article highlighted a GF Value of $2.57 versus the current price, underscoring extreme overvaluation. The DeepValue master report reinforces this gap, assigning a POTENTIAL SELL rating with a bear case of $60, as revenue growth remains gated by unpredictable China export permits for indium phosphide substrates. While Q1'26 showed a sharp operational inflection—substrate revenue up 74% YoY and gross margin swinging to 29.6%—the geographic mix remained heavily concentrated in China (61%) with North America at only 1%, as management states it cannot predict when it will resume U.S. shipments. The April 2026 equity raise of ~$632.5M provides liquidity but raises the burden of proof on deployment into capacity expansion, and early insider sales clusters signal caution. Without a clear catalyst for U.S. permit issuance or a step-change in Western revenue, the stock prices a smooth ramp that the company's own disclosures contradict.

Implication

AXTI's 8.2% drop confirms that the market is beginning to price in the core risk: unpredictable export permits that block InP shipments to the U.S., leaving North America at 1% of revenue. The stock at $84.31 still prices a rapid operational turnaround, but filings show management cannot estimate permit timing and the backlog clearance depends on approvals, not demand. With the GF Value suggesting a 97% overvaluation and the DeepValue bear case at $60, investors should trim positions unless a U.S. permit is observed within the next 90 days. The thesis remains a potential sell until either permits broaden or revenue mix shifts materially; any bounce without permit news is a selling opportunity.

Thesis delta

The 8.2% price decline is consistent with the existing sell thesis and does not alter the fundamental outlook. It reinforces the downside risk that the market is slowly repricing the premium embedded in the stock, moving the price closer to the $60–70 attractive entry range. No catalyst has emerged to improve the probability of the bull case; the thesis remains that the stock is overvalued until U.S. export permits are issued and non-China revenue expands materially.